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Abstract
Fibromyalgia Syndrome (FMS) is a chronic condition causing 
pain, stiffness, and tenderness of the muscles, tendons, and 
joints. It is also characterized by restless sleep, tiredness, fatigue, 
anxiety, depression, and disturbances in bowel functions. The 
etiology of fibromyalgia remains unknown, but recent advances 
and discoveries have helped to unravel some of the mysteries 
of this disease. Research highlights some of the biochemical, 
metabolic, and immunoregulatory abnormalities associated with 
fibromyalgia. Management of FMS at the present time is very 
difficult as it has multiple etiological factors and psychological 
predispositions; however, a patient centered approach is essential 
to handle this problem.
Keywords: Fibromyalgia; Clinical features; Quality of life; 
Pathophysiology and management of fibromyalgia.
Introduction 
Pain with its devastating and demoralizing effects remains 
a challenging problem for both patients and care givers.1 
Fibromyalgia is one of the most common diseases affecting the 
muscles manifested with pain, stiffness, and tenderness of the 
muscles, tendons, and joints. The painful tissues involved are 
not accompanied by tissue inflammation.2-3 Therefore, despite 
potentially disabling body pain; patients with fibromyalgia do not 
develop tissue damage or deformity.4-5 The pain of fibromyalgia is 
generally widespread, involving both sides of the body. Pain usually 
affects the neck, buttocks, shoulders, arms, the upper back, and the 
chest. "Tender points" are localized tender areas of the body that 
can bring on widespread pain and muscle spasm when touched. 6-7
FMS typically presents in young or middle-aged females 
as persistent widespread pain, stiffness, fatigue, disrupted 
unrefreshing sleep, and cognitive difficulties, often accompanied by 
multiple other unexplained symptoms, anxiety and/or depression, 
and functional impairment of daily living activities.8-9 There is an 
overall 6% to 15% prevalence rate in the United States with a five 
times greater incidence among women than men. In rheumatology 
clinics, the rate of new diagnosis is approximately 10% to 20%, 
whereas in non-specialized settings, the rate is 2.1% to 5.7%.10-11
Clinicians should be familiar with the signs and symptoms 
of fibromyalgia and diagnose the condition with minimum 
investigation.12 Since the symptoms of fibromyalgia wax and 
wane related to stresses,13 treatment (as with that of other chronic 
diseases) is an ongoing process rather than management of a single 
episode.
In terms of conditions associated with fibromyalgia; there are 
certain conditions associated with fibromyalgia.17-19 (Table 1)
Pathophysiology
Although the etiology remains unclear, characteristic alterations 
in the pattern of sleep and changes in neuroendocrine transmitters 
such as serotonin, substance P, growth hormone and cortisol 
suggest that regulation of the autonomic and neuro-endocrine 
system appears to be the basis of the syndrome. Fibromyalgia is 
not a life-threatening, deforming, or progressive disease. Anxiety 
and depression are the most common association.14 Aberrant pain 
processing, which can result in chronic pain, may be the result of 
several interplaying mechanisms. Central sensitization, blunting 
of inhibitory pain pathways and alterations in neurotransmitters 
lead to aberrant neuro-chemical processing of sensory signals in 
the CNS, thus lowering the threshold of pain and amplification of 
normal sensory signals causing constant pain.15-16
The frequent co-morbidity of fibromyalgia with mood 
disorders suggests a major role for the stress response and for 
neuroendocrine abnormalities. The hypothalamic pituitary axis 
(HPA) is a critical component of the stress-adaptation response.17 
In FMS, stress adaptation response is disturbed leading to stress 
induce symptoms. Psychiatric co-morbidity has been associated 
with FMS and needs to be identified during the consultation 
process, as this requires special consideration during treatment.18
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Table 1: Conditions associated with fibromyalgia. 
Musculoskeletal Genitourinary Gastro intestinal Miscellaneous
• Nondermatomal paresthesia
• Temporo mandibular joint syndrome
• Hyper mobility syndrome
• Restless legs syndrome
• Rheumatoid arthritis
• Systemic lupus erythematosus
• Sjögren syndrome
• Osteoarthritis
• Chronic fatigue syndrome
• Carpal tunnel syndrome
• Myofascialpain syndrome
• Dysmenorrhea
• Interstitial cystitis
• Vulvodynia
• Female urethral syndrome
• Vulvar vestibulitis
• Premenstrual syndrome
• Irritable bowel syndrome
• Esophageal dysmotility
• Tension/migraine headaches
• Mitral valve prolapsed
• Allergy
• Vestibular disorders
• Ocular disturbances
• Anxiety disorders
• Reynaud phenomenon
• Thyroid dysfunction
• Lyme disease
• Hyperventilation
• Cognitive dysfunction
Assessment of Fibromyalgia
Although fibromyalgia is the most common chronic widespread 
pain condition, it is often under diagnosed. The diagnosis of 
fibromyalgia has been shown to increase patient satisfaction and 
reduce healthcare utilization.
The assessment of Fibromyalgia is based on the criteria for 
the Classification of Fibromyalgia by the American College of 
Rheumatology, (ACR) 1990.19-21 The criterion involves:
• History of widespread pain has been present for at least three 
months.
• Pain in both sides of the body pain above and below the 
waist. Pain is considered widespread when all of the following are 
present:
•  Pain in 11 of 18 tender point sites on digital palpation (both 
side of the body): Occiput (2),Low cervical (2),Trapezius (2), 
Supraspinatus (2), Second rib (2), Lateral epicondyle (2), Gluteal 
(2), Greater trochanter (2), Knee (2).
A tender point hurts only at the area where pressure (enough 
to cause the examiner's nail bed to blanch, or about 4 kg) is 
applied, and there is no referred pain. An instrument known as a 
dolorimeter can be used to apply exactly 4 kg of pressure over the 
tender points during the examination.22
New Diagnostic Criteria
Recently, ACR is proposing a new set of diagnostic criteria for 
fibromyalgia that includes common symptoms such as fatigue, 
sleep disturbances, and cognitive problems, as well as pain (Table 
2). The tender point test is being replaced with a widespread pain 
index and a symptom severity (SS) score. The new criteria appear 
in a one-page symptom checklist format that will hopefully be 
more suitable for use in the primary-care setting.23 A tender point 
evaluation is no longer required although a full physical exam is 
still recommended along with other diagnostic tests to identify 
causes for the patients' symptoms besides fibromyalgia. In place of 
the tender point count, patients (or their physician) may endorse 
19 body regions in which pain has been experienced during the 
past week. One point is given for each area, so the score is between 
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0-19. This number is referred to as the Widespread Pain Index 
(WPI) and it is one of the two required scores needed for a doctor 
to make a diagnosis of fibromyalgia.
The second part of the score required to assess the diagnosis of 
fibromyalgia involves the evaluation of a person's symptoms. The 
patient ranks specific symptoms on a scale of 0-3. These symptoms 
include: Fatigue, Waking unrefreshed, Cognitive symptoms, 
Somatic (physical) symptoms in general (such as headache, 
weakness, bowel problems, nausea, dizziness, numbness/tingling, 
hair loss). The numbers assigned to each are added up, for a total 
of 0-12.
The diagnosis is based on both the WPI score and the SS score 
either:
• WPI of at least 7 and SS scale score of at least 5, OR
• WPI of 3-6 and SS scale score of at least 9.
Table 2: New ACR Diagnostic Criteria.
Fatigue
Waking 
unrefreshed
Cognitive 
symptoms
0 = No problem 0 = No problem 0 = No problem
1 = Slight or mild 
problems;
Generally mild or 
intermittent
1 = Slight or mild 
problems;
Generally mild or 
intermittent
1 = Slight or mild 
problems;
Generally mild or 
intermittent
2 = Moderate; 
considerable 
Problems; often 
present
and/or at a 
moderate level
2 = Moderate; 
considerable
Problems; often 
present and/or at a 
moderate level
2 = Moderate; 
considerable
Problems; often 
present and/or at a 
moderate level
3 = severe: 
pervasive, 
continuous, 
Life disturbing 
problems
3 = severe: 
pervasive, 
continuous, 
Life disturbing 
problems
3 = severe: 
pervasive, 
continuous, 
Life disturbing 
problems
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Laboratory Investigations
Laboratory testing, such as complete blood count, erythrocyte 
sedimentation rate, rheumatoid factor, antinuclear antibody, 
thyroid-stimulating hormone, T3, T4, creatinine phosphokinase, 
a serum muscle enzyme, vitamin D, ESR, CRP, renal function, 
and liver function tests are necessary to rule out other disorders. 
X-rays, blood tests, specialized scans such as nuclear medicine and 
CT scan muscle biopsy are normal in cases of fibromyalgia.
Management of Fibromyalgia
By the time many fibromyalgia patients reach the primary care 
setting or practice, they may have been seen by multiple healthcare 
providers. Patients are often frustrated or discouraged after 
receiving inadequate answers or diagnosis of their chronic ailments. 
Many are relieved to learn that there is an actual diagnosis and 
possible treatment options for their symptoms.24-25
Patients should participate in developing and initiating a care 
plan. Being a participant in their care will help the patient to 
assume control of their lives and focus on positive lifestyle changes 
rather than on chronic dysfunction. Patients must try to avoid 
exacerbating factors and limit anxiety and stress.26-27
A great majority of FMS patients can be managed well 
by Family Physicians in ambulatory care by managing stress, 
depression, pain and life style modification.28 CNS agents, 
antidepressants, muscle relaxants, or anticonvulsants are the most 
successful pharmacotherapies.
Therapeutic Measures in FMS
Medications have a limited role in FMS treatment to limit 
symptoms, so patients can participate in non-pharmacologic 
modalities that provide long-term disease management such as 
exercise, behavioral and education. Non pharmacologic therapies 
should be used when possible. 29
Drugs
There are different pain medications which are useful in the 
management of FMS. Paracetamol, NSAIDs have been used but 
pain usually do not respond to them. Acetaminophen may ease the 
pain and stiffness caused by fibromyalgia. Besides analgesics, there 
are drugs used like antidepressant, anti convulsant, Dopamine 
agonist and Growth hormone.
Antidepressant Agents
Antidepressants have a long history in the treatment of chronic 
pain syndromes. The tricyclic antidepressants, selective serotonin 
reuptake inhibitors (SSRIs), or combinations of both, produce 
mild to moderate improvement in symptoms. Dosages should be 
gradually increased, not to exceed the recommended maximum 
for the drug. Even patients who are able to tolerate very small 
amounts of these medications may derive benefit from them. 
Antidepressants are most commonly used because of their effect on 
serotonin. Duloxetine, which is a Serotonin and Norepinephrine 
reuptake inhibitor is used successfully. Dopamine agonists (e.g., 
pramipexole), Sodium Oxybate and growth hormone therapy have 
recently been introduced for FMS.30-31
Life Style Modifications
Stress Management: Many patients with fibromyalgia have 
increased levels of stress and feelings of depression, anxiety, 
and frustration. Several treatment options are available such as 
cognitive behavioral therapy; including relaxation training, group 
therapy, and biofeedback, which are some of the useful options.32
Exercise: Physical activity can be taken in many ways, including 
activities such as walking, jogging or sports.33 Exercise is a way of 
responding to stress which allows the discharge of the energy the 
body is anticipating. 34
Alternative Therapies: Chinese herbal medications, Chinese 
herbal tea, acupuncture, Tai-chi are the different modalities 
available but more research is required in these fields.35-38 It has also 
been suggested that acupuncture triggers the release of endorphins 
into the blood stream and are body's natural pain relievers.39
Conclusion
Fibromyalgia is a common rheumatologic syndrome characterized 
by heightened pain sensitivity, fatigue, sleep disturbance, and 
other symptoms as a result of dysregulation of neurophysiologic 
function. Many theories of etiology are under investigation. With 
the proper treatment coupled with a caring and well informed 
physician; patients with fibromyalgia should be able to improve 
function and reduce pain. A variety of neuro-modulatory agents are 
showing capability of beneficially affecting the symptom domains 
of patients with fibromyalgia. Treatment options currently exist 
to assist patients in relieving symptoms and preventing flare-ups. 
Prompt diagnosis and treatment of fibromyalgia patients may 
produce substantial improvement in quality of life.
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